Zhuofeng Lin

Zhuofeng Lin


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2010 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
JWJennifer Mp Woo
Jennifer Mp Woo
ZLZhuofeng Lin
Zhuofeng Lin
Mohamad NavabMohamad Navab
Mohamad Navab
CDCasey Van Dyck
Casey Van Dyck
YTYvette Trejo-Lopez
Yvette Trejo-Lopez
BTBetty P Tsao
Betty P Tsao
Introduction: The purpose of this study was to evaluate the effects of L-4F, an apolipoprotein A-1 mimetic peptide, alone or with pravastatin, in apoE-/-Fas-/-C57BL/6 mice that spontaneously develop immunoglobulin G (IgG) autoantibodies, glomerulonephritis, osteopenia, and atherosclerotic lesions on a normal chow diet.Methods: Female mice, starting at eight to nine weeks of age, were treated for 27 weeks with 1) pravastatin, 2) L-4F, 3) L-4F plus pravastatin, or 4) vehicle control, followed by disease phenotype assessment.Results: In preliminary studies, dysfunctional, proinflammatory high-density lipoproteins (piHDL) were decreased six hours after a single L-4F, but not scrambled L-4F, injection in eight- to nine-week old mice. After 35 weeks, L-4F-treated mice, in the absence/presence of pravastatin, had significantly smaller lymph nodes and glomerular tufts (PL,LP< 0.05), lower serum levels of IgG antibodies to double stranded DNA (dsDNA) (PL< 0.05) and oxidized phospholipids (oxPLs) (PL,LP< 0.005), and elevated total and vertebral bone mineral density (PL,LP< 0.01) compared to vehicle controls. Although all treatment groups presented larger aortic root lesions compared to vehicle controls, enlarged atheromas in combination treatment mice had significantly less infiltrated CD68+macrophages (PLP< 0.01), significantly increased mean α-actin stained area (PLP< 0.05), and significantly lower levels of circulating markers for atherosclerosis progression, CCL19 (PL,LP< 0.0005) and VCAM-1 (PL< 0.0002).Conclusions: L-4F treatment, alone or with pravastatin, significantly reduced IgG anti-dsDNA and IgG anti-oxPLs, proteinuria, glomerulonephritis, and osteopenia in a murine lupus model of accelerated atherosclerosis. Despite enlarged aortic lesions, increased smooth muscle content, decreased macrophage infiltration, and decreased pro-atherogenic chemokines in L-4F plus pravastatin treated mice suggest protective mechanisms not only on lupus-like disease, but also on potential plaque remodeling in a murine model of systemic lupus erythematosus (SLE) and accelerated atherosclerosis.